促红细胞生成素治疗创伤性脑损伤研究中渗透疗法的事后分析:与急性肾损伤和死亡率的相关性
该研究为促红细胞生成素治疗创伤性脑损伤随机对照试验(NCT00987454)的事后分析,纳入7个国家29所大学附属教学医院的568例在ICU治疗48小时且无急性肾损伤的患者,其中43例(7%)使用甘露醇、170例(29%)使用高渗盐水。按KDIGO分类定义急性肾损伤,采用Cox回归分析早期(前2天)渗透疗法与至ICU出院时急性肾损伤及至180天死亡的关系。结果显示甘露醇组急性肾损伤发生率35% vs 10%(p<0.001),高渗盐水组23% vs 10%(p<0.001);竞争风险分析中甘露醇(HR 2.3,95%CI 1.2-4.3,p=0.01)而非高渗盐水(HR 1.6,95%CI 0.9-2.8,p=0.08)与急性肾损伤独立相关;甘露醇(HR 2.1,95%CI 1.1-4.1,p=0.03)和高渗盐水(HR 1.8,95%CI 1.02-3.2,p=0.04)均与死亡时间相关。作者认为需进一步评估创伤性脑损伤中渗透疗法的使用与选择。
要点
- 在568例ICU治疗的创伤性脑损伤患者中,早期使用甘露醇者急性肾损伤发生率为35% vs 10%(p<0.001)。
- 竞争风险分析中甘露醇与急性肾损伤独立相关(HR 2.3,95%CI 1.2-4.3,p=0.01)。
- 高渗盐水与急性肾损伤无独立关联(HR 1.6,95%CI 0.9-2.8,p=0.08),但高渗盐水组急性肾损伤发生率23% vs 10%(p<0.001)。
- 甘露醇(HR 2.1,95%CI 1.1-4.1,p=0.03)和高渗盐水(HR 1.8,95%CI 1.02-3.2,p=0.04)均与至180天死亡时间相关。
- 作者认为需进一步评估创伤性脑损伤中渗透疗法的使用与选择。
适用人群与场景
- 在ICU治疗的创伤性脑损伤患者,来自促红细胞生成素治疗创伤性脑损伤试验(NCT00987454),共568例,ICU治疗48小时且无急性肾损伤。
- 其中43例(7%)接受甘露醇,170例(29%)接受高渗盐水。
诊断标准与关键阈值
- 急性肾损伤分期采用肾脏病改善全球结局(KDIGO)分类,急性肾损伤定义为自入院肌酐起任何KDIGO分期变化。
研究设计与关键结果
- 设计:促红细胞生成素治疗创伤性脑损伤随机对照试验的事后分析,纳入每日甘露醇和高渗盐水使用数据;场所为7个国家29所大学附属教学医院;无干预。
- 急性肾损伤在甘露醇组发生率35% vs 10%(p<0.001),高渗盐水组23% vs 10%(p<0.001)。
- 竞争风险分析纳入与急性肾损伤相关的因素后,甘露醇与至急性肾损伤时间独立相关(HR 2.3,95%CI 1.2-4.3,p=0.01),高渗盐水无独立关联(HR 1.6,95%CI 0.9-2.8,p=0.08)。
- 预测至死亡时间的Cox模型中,甘露醇(HR 2.1,95%CI 1.1-4.1,p=0.03)和高渗盐水(HR 1.8,95%CI 1.02-3.2,p=0.04)均与死亡时间相关。
证据类型、等级与局限
- 证据类型:随机对照试验的事后分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,研究结果提示需进一步评估创伤性脑损伤中渗透疗法的使用与选择。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Mannitol and hypertonic saline are used to treat raised intracerebral pressure in patients with traumatic brain injury, but their possible effects on kidney function and mortality are unknown.
DESIGN: A post hoc analysis of the erythropoietin trial in traumatic brain injury (ClinicalTrials.gov NCT00987454) including daily data on mannitol and hypertonic saline use.
SETTING: Twenty-nine university-affiliated teaching hospitals in seven countries.
PATIENTS: A total of 568 patients treated in the ICU for 48 hours without acute kidney injury of whom 43 (7%) received mannitol and 170 (29%) hypertonic saline.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: We categorized acute kidney injury stage according to the Kidney Disease Improving Global Outcome classification and defined acute kidney injury as any Kidney Disease Improving Global Outcome stage-based changes from the admission creatinine. We tested associations between early (first 2 d) mannitol and hypertonic saline and time to acute kidney injury up to ICU discharge and death up to 180 days with Cox regression analysis. Subsequently, acute kidney injury developed more often in patients receiving mannitol (35% vs 10%; p < 0.001) and hypertonic saline (23% vs 10%; p < 0.001). On competing risk analysis including factors associated with acute kidney injury, mannitol (hazard ratio, 2.3; 95% CI, 1.2-4.3; p = 0.01), but not hypertonic saline (hazard ratio, 1.6; 95% CI, 0.9-2.8; p = 0.08), was independently associated with time to acute kidney injury. In a Cox model for predicting time to death, both the use of mannitol (hazard ratio, 2.1; 95% CI, 1.1-4.1; p = 0.03) and hypertonic saline (hazard ratio, 1.8; 95% CI, 1.02-3.2; p = 0.04) were associated with time to death.
CONCLUSIONS: In this post hoc analysis of a randomized controlled trial, the early use of mannitol, but not hypertonic saline, was independently associated with an increase in acute kidney injury. Our findings suggest the need to further evaluate the use and choice of osmotherapy in traumatic brain injury.
参考来源
- Skrifvars MB, Bailey M, Moore E, et al. A Post Hoc Analysis of Osmotherapy Use in the Erythropoietin in Traumatic Brain Injury Study-Associations With Acute Kidney Injury and Mortality. Crit Care Med. 2021. PMID: 33566466. doi:10.1097/CCM.0000000000004853
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。